^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ILB-2109

    i
    Other names: ILB-2109, ILB2109, WTS-001
    Associations

    News

    Trials
    Company:
    Innolake Biopharma
    Drug class:
    Adenosine A2A receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Innolake Biopharm | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • ILB-2109
    5ms
    A Study of ILB2109 in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=48, Recruiting, Innolake Biopharm | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Nov 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    ILB-2109
    over1year
    A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=200, Not yet recruiting, Innolake Biopharm
    New P1/2 trial • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • ILB-2109